Table 4.
Case 2 | |||
---|---|---|---|
Time of use to illness: 8 m o n t h s* | *↓ | ||
| |||
Time of use to discontinuation: 8 m o n t h s* | *↓ | ||
| |||
Time of presentation to liver c l i n i c* | *↓ | ||
| |||
Duration in months | 4 | 4.5 | 5 |
| |||
Treatment | Prednisone | ||
| |||
Liver function tests (normal values) | |||
Total bilirubin (0.8–1.2 mg/dL) | 2.0 | 1.4 | 0.6 |
ALT (5–40 U/L) | 443 | 60 | 30 |
AST (10–40 U/L) | 478 | 50 | 38 |
ALP (30–120 U/L) | 188 | 153 | 98 |
INR (0.8–1.2) | 2.0 | — | 1.3 |
| |||
Autoimmune antibodies | |||
Anti-nuclear antibody | Negative | 1 : 20 | — |
Anti-smooth muscle antibody | Negative | — | — |
Liver biopsy findings | — | — | |
| |||
Lobular | |||
Necrosis | Central | — | — |
Infiltrates | Plasmacytic | — | — |
Other findings | Disarray, apoptosis | — | — |
| |||
Portal and periportal | |||
Cholangiolar proliferation | Moderate | — | — |
Infiltrate severity | Moderate | — | — |
Infiltrate predominant type | Plasmacytic | — | — |
Fibrosis | Fibronecrosis | — | — |